Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2020 Jan;35(1):e2718.
doi: 10.1002/hup.2718. Epub 2019 Dec 14.

Differential benefits of olanzapine on executive function in schizophrenia patients: Preliminary findings

Neeti D Mehta  1   2 , Michelle J Won  1   2 , Shelly L Babin  1 , Saumil S Patel  3 , Adel A Wassef  4 , Alice Z Chuang  5 , Anne B Sereno  1   6   7
Affiliations
Controlled Clinical Trial

Differential benefits of olanzapine on executive function in schizophrenia patients: Preliminary findings

Neeti D Mehta et al. Hum Psychopharmacol. 2020 Jan.

Abstract

Objective: Schizophrenia patients show executive function (EF) impairments in voluntary orienting as measured by eye-movements. We tested 14 inpatients to investigate the effects of the antipsychotic olanzapine on EF, as measured by antisaccade eye-movement performance.

Methods: Patients were tested at baseline (before olanzapine), 3-5 days post-medication, and 12-14 days post-medication. Patients were also assessed on the Positive and Negative Syndrome Scale (PANSS) to measure the severity of schizophrenia-related symptoms, and administered the Stroop task, a test of EF. Nine matched controls were also tested on the antisaccade and Stroop.

Results: Both groups showed improvement on Stroop and antisaccade; however, the schizophrenia group improved significantly more on antisaccade, indicating an additional benefit of olanzapine on EF performance. Patients with poorer baseline antisaccade performance (High-Deficit) showed significantly greater improvement on the antisaccade task than patients with better baseline performance (Low-Deficit), suggesting that baseline EF impairment predicts the magnitude of cognitive improvement with olanzapine. These subgroups showed significant and equivalent improvement on PANSS scores, indicating that improvement on the antisaccade task with olanzapine was not a result of differences in magnitude of clinical improvement.

Conclusions: This preliminary study provides evidence that olanzapine may be most advantageous for patients with greater baseline EF deficits.

Keywords: Stroop task; antipsychotics; antisaccade task; cognitive heterogeneity; executive function; eye-movements.

PubMed Disclaimer

References

REFERENCES

    1. Agid, O., Seeman, P., & Kapur, S. (2006). The “delayed onset” of antipsychotic action-An idea whose time has come and gone. Journal of Psychiatry & Neuroscience, 31(2), 93-100.
    1. Amador, S. C., Hood, A. J., Schiess, M. C., Izor, R., & Sereno, A. B. (2006). Dissociating cognitive deficits involved in voluntary eye movement dysfunctions in Parkinson's disease patients. Neuropsychologia, 44(8), 1475-1482. https://doi.org/10.1016/j.neuropsychologia.2005.11.015
    1. Babin, S. L., Hood, A. J., Wassef, A. A., Williams, N. G., Patel, S. S., & Sereno, A. B. (2011). Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: A saccadic eye movement study. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 35(7), 1753-1764. https://doi.org/10.1016/j.pnpbp.2011.06.004
    1. Benson, P. J., Beedie, S. A., Shephard, E., Giegling, I., Rujescu, D., & St. Clair, D. (2012). Simple viewing tests can detect eye movement abnormalities that distinguish schizophrenia cases from controls with exceptional accuracy. Biological Psychiatry, 72(9), 716-724. https://doi.org/10.1016/j.biopsych.2012.04.019
    1. Bilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., … Lieberman, J. A. (2002). Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 159(6), 1018-1028. https://doi.org/10.1176/appi.ajp.159.6.1018

Publication types

LinkOut - more resources